| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Top-line Data example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Top-line Data example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Top-line Data example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Olema Pharmaceuticals, Inc.$11.91
-0.47 (-3.83%)
C 42Pipeline Score Richly Valued Pharma · Clinical
Market Cap
1.19 B
EPS
-2.03
P/E Ratio
-
Value Trade
15.22 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
49.23 M
Operating CF
-45.99 M
Total Assets
530.64 M
Total Liabilities
50.17 M
Equity
480.48 M
D/E Ratio
12,345
1.11 %
Week
-18.08 %
1 Month
-41.66 %
3 Month
-36.34 %
6 Month
-46.56 %
5 Year
-69.6 %
All Time
Cash Data
Cash Position
505.35 M
Monthly Burn
15.33 M
Runway
31.3 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
983.80 K
52 Week Range
3.89 - 36.26
% held by Insiders
18.93 %
% held by Institutions
99.98 %
Enterprise Value
693.52 M
Total Shares
87.32 M
Short %
24.31 %
Float Shares
57.72 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Olema Pharmaceuticals, Inc.
299Total events
8Upcoming
28Tier-1 (high impact)
2020 – 2029Coverage
Upcoming catalysts 8
2026-H2
T1Topline Readout
Top-line data from OPERA-01 trial evaluating palazestrant as monotherapy in second- and third-line
Event history 291
Q3 2026
◆Topline ReadoutPalazestrantApprovedClinical Data
Fall 2026 topline data for OPERA-01 monotherapy
2/3L ER+/HER2- metastatic breast cancersource ↗
Jun 9, 2026
Jun 1, 2026
◆Poster PresentationPalazestrantApprovedPresentation
Trial-in-progress poster for OPERA-02 at ASCO 2026
ER+/HER2- metastatic breast cancersource ↗
May 30, 2026
◆Poster PresentationOP-3136Presentation
Initial clinical data for OP-3136 poster presentation at ASCO 2026
advanced solid tumors; ER+, HER2- advanced breast cancersource ↗
May 30, 2026
◆Topline ReadoutOP-3136Clinical Data
Preliminary Phase 1 data for OP-3136 (data cut-off March 2, 2026)
advanced solid tumorssource ↗
May 26, 2026
▲Partnership / LicenseOP-3136Corporate
Clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136 in combination with darolutamide
metastatic castration-resistant prostate cancersource ↗
May 2026
◆Oral PresentationOP-3136Presentation
Initial clinical data from Phase 1 study of OP-3136 presented at ASCO
ER+/HER2- breast cancersource ↗
May 2026
●Poster PresentationPalazestrantApprovedPresentation
Trial-in-progress poster for OPERA-02 at ASCO
ER+/HER2- metastatic breast cancersource ↗
Apr 29, 2026
Drug Pipeline Intelligence
C42
Pipeline Score $156M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.1x
rNPV / MCap Top 61%
Micro Cap (rank 356 of 911)
Percentile RankOlema Pharmaceuticals, Inc. carries a moderate pipeline score (42/100), with $391M risk-adjusted pipeline value, led by Palazestrant in Breast Cancer (Phase 3), across $94B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Palazestrant Small molecule | Breast Cancer | Phase 3 | NCT05266105 | 42% | $222M | ACTIVE NOT_RECRUITING | 1,570 | AVERAGE | D (36) | Mar 1, 2026 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
OP-3136 | advanced solid tumors | Phase 1 | 2026-05-22 | over two-thirds of patients showing tumor size reductions | Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting Read More | |
OP-3136 | advanced solid tumors | Phase 1 | 2026-05-22 | over two-thirds of patients showing tumor size reductions | Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting Read More | |
OP-3136 | advanced solid tumors | Phase 1 | 2026-05-22 | over two-thirds of patients showing tumor size reductions | Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OLMA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OLMA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
OLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
Olema Pharmaceuticals announced the granting of stock options to six new employees, totaling 176,150 shares, effective June 1, 2026. This move is part of the company's 2022 Inducement Plan and complies with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over four years and have an exercise price of $12.71 per share.
Read more →OLMAOlema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA (darolutamide) in Metastatic Castration-Resistant Prostate Cancer • Study to eva
Olema Oncology has announced a clinical trial collaboration with Bayer to evaluate OP-3136 in combination with NUBEQA for metastatic castration-resistant prostate cancer. This Phase 1b/2 study will include approximately 36 patients and aims to assess safety, tolerability, and preliminary anti-tumor activity. This agreement is significant as it represents the first clinical trial for OP-3136 in a combination scenario, expanding its potential therapeutic applications in oncology. Initial clinical data from a separate Phase 1 study of OP-3136 will be presented at the upcoming ASCO Annual Meeting.
Read more →OLMAOlema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Olema Oncology announced preliminary clinical data from the Phase 1 study of OP-3136, a KAT6 inhibitor, showing promising anti-tumor activity and acceptable tolerability. The data will be presented at the ASCO Annual Meeting on May 30, 2026. The study includes patients with advanced breast cancer, prostate cancer, and lung cancer, with over two-thirds of patients showing tumor size reductions.
Read more →OLMA▲ +6.6%on this newsshared move
Olema Oncology to Participate in Upcoming Investor Conferences - May 19, 2026
Olema Oncology has announced its participation in several upcoming investor conferences, including the TD Cowen 7th Annual Oncology Innovation Summit and the Jefferies Global Healthcare Conference. The company is focused on developing targeted therapies for breast cancer and is advancing its lead product candidate, palazestrant, in Phase 3 trials. Additionally, Olema is developing another candidate, OP-3136, in a Phase 1 study.
Read more →OLMA▼ -6%on this news
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
Olema Oncology reported its first quarter 2026 financial results, highlighting significant advancements in its clinical pipeline, particularly with palazestrant and OP-3136. The company anticipates top-line data from the Phase 3 OPERA-01 trial this fall and continues to enroll patients in the OPERA-02 trial. Despite a net loss of $53.1 million, Olema maintains a strong cash position of $505.3 million.
Read more →OLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. announced the grant of stock options to five new employees under the 2022 Inducement Plan. The total of 154,700 shares will vest over four years, with a marked exercise price of $14.32 per share. This initiative is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to bolster the company's talent acquisition efforts. Olema continues to advance its growing expertise in targeted therapies for breast cancer, indicated by ongoing clinical trials for its lead product candidate, palazestrant.
Read more →OLMAOlema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
Olema Oncology has appointed Prakash Raman, Ph.D., to its Board of Directors, enhancing its leadership team during a critical phase of development. Dr. Raman brings over two decades of biopharmaceutical experience, which positions him to play a crucial role as the company advances its lead program, palazestrant, through Phase 3 trials. He is expected to contribute significantly to Olema's growth strategy and development efforts, particularly with the anticipated pivotal data for OPERA-01 later in the year.
Read more →OLMAOlema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
Olema Oncology announced it will showcase initial clinical data from the Phase 1 study of OP-3136 at the 2026 ASCO Annual Meeting scheduled for May 29 to June 2 in Chicago. The presentation will include preliminary results from a first-in-human study of OP-3136 as a monotherapy and in combination with endocrine therapy for advanced breast cancer. Additionally, a trial-in-progress poster for the Phase 3 OPERA-02 trial concerning palazestrant will also be presented. This event marks a significant step for Olema in advancing its oncology pipeline.
Read more →OLMAOlema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Olema Oncology announced new preclinical data for palazestrant and OP-3136 at the AACR Annual Meeting. The data highlights palazestrant's ability to block estrogen receptor signaling and its synergistic effect with OP-3136 in combating metastatic breast cancer. The findings support ongoing clinical trials and the potential for improved treatment outcomes.
Read more →OLMA▼ -9.3%on this news
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Olema Oncology announced its intention to present two preclinical posters at the AACR Annual Meeting in San Diego, taking place from April 17-22, 2026. The presentations will highlight new data on Palazestrant and OP-3136, which are being developed for breast cancer treatment. Palazestrant is being investigated for its ability to antagonize estrogen receptors and show efficacy in ER-positive breast cancer. OP-3136 is in early clinical studies and is noted for its synergistic effects with established endocrine therapies.
Read more →OLMA▲ +12.8%on this newsshared move
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results • On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monother
Olema Oncology reported its financial and operational results for Q4 and full year 2025, highlighting significant progress in its clinical programs for palazestrant aimed at treating ER+/HER2- metastatic breast cancer. The company is on track to deliver top-line data from the Phase 3 OPERA-01 trial in fall 2026, while also advancing other trials including OPERA-02 and a combination study with Pfizer's atirmociclib. Olema strengthened its financial position with a $218.5 million public offering, preparing for a potential commercial launch in late 2027. However, the company also noted a rising net loss attributed to increased spending on clinical trials.
Read more →OLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 3, 2026
Olema Oncology announced the granting of stock options to four new employees, totaling 205,000 shares, effective March 2, 2026. This move is part of the company's 2022 Inducement Plan and aligns with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, promoting long-term employment and commitment to the company's goals in breast cancer treatment.
Read more →OLMA▲ +6.2%on this news
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
Olema Oncology announced that its CEO, Sean P. Bohen, will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The presentation will be available via a live webcast on Olema's investor relations website. Olema is focused on developing targeted therapies for breast cancer, including its lead candidate, palazestrant, which is currently undergoing Phase 3 trials. Furthermore, the company is also developing a KAT6 inhibitor in Phase 1 clinical study.
Read more →OLMA▼ -5%on this news
Olema Oncology to Participate in Upcoming February 2026 Investor Conferences
Olema Oncology will participate in several investor conferences in February 2026, including the Guggenheim Securities Emerging Outlook: Biotech Summit and Citi's 2026 Virtual Oncology Leadership Summit. The company is dedicated to developing targeted therapies for breast cancer and is advancing its pipeline, including two key product candidates currently in clinical trials.
Read more →OLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 3, 2026
Olema Pharmaceuticals announced the granting of stock options to two new employees, totaling 24,000 shares. This move, approved by the Compensation Committee, aligns with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new hires. The options will vest over four years and have an exercise price of $25.65 per share.
Read more →OLMAOlema Oncology to Participate in Upcoming Investor Conferences
Olema Pharmaceuticals, Inc. has announced its participation in several upcoming investor conferences, indicating its active outreach to investors. The conferences include the Guggenheim Securities Emerging Outlook: Biotech Summit, Citi's 2026 Virtual Oncology Leadership Summit, and the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Olema is committed to improving outcomes for patients with breast cancer and has a focus on advancing its drug pipeline, including two ongoing Phase 3 clinical trials.
Read more →OLMAOlema Oncology Announces Departure of Chief Operating and Financial Officer
Olema Oncology announced the departure of Shane Kovacs, its Chief Operating and Financial Officer, effective January 30, 2026. Kovacs will continue to consult for the company until August 1, 2026. The company praised his contributions to its growth and development, particularly in advancing its lead product, palazestrant, through clinical trials. Olema is now searching for a new CFO.
Read more →OLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 5, 2026
Olema Oncology has granted stock options to eight new employees, totaling 223,500 shares, effective January 2, 2026. This move is part of the company's 2022 Inducement Plan and complies with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over four years, supporting Olema's commitment to developing targeted therapies for breast cancer.
Read more →OLMAOlema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
Olema Oncology announced that its CEO, Sean P. Bohen, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2025. The presentation will focus on the company's advancements in targeted therapies for breast cancer, including their lead product candidate, palazestrant, currently in Phase 3 trials. A live webcast and recording of the presentation will be available on their Investor Relations website.
Read more →OLMAAdvancing medicines for breast cancer and beyond Corporate Overview January 2025 Forward-looking statements and legal disclaimer This presentation contains forward-looking statements made pursuant to the safe harbor prov
Olema Pharmaceuticals is advancing its efforts in the treatment of metastatic breast cancer with its drug candidates palazestrant and OP-3136. The company highlights the significant market opportunity in the ER+/HER2- population, potentially exceeding $20 billion. Their clinical trials aim to establish palazestrant as a leading therapy option in both first-line and second/third-line treatments. However, Olema also acknowledges various risks associated with the development and approval processes for these therapies.
Read more →OLMA▲ +5.3%on this news· ran to +28% by day 3
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
Olema Pharmaceuticals, Inc. has announced its participation in the 8th Annual Evercore Healthcare Conference, scheduled for December 3, 2025. The company, which focuses on targeted therapies for breast cancer, will engage in a fireside chat, the details of which can be accessed through live webcasts on their investor relations website. Olema continues to develop its pipeline, including innovative treatments like palazestrant, aimed at improving outcomes for patients with endocrine-driven cancers.
Read more →OLMA▲ +13.3%on this news· ran to +34% by day 3shared move
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Olema Oncology has successfully closed a public offering of 11,500,000 shares of its common stock, generating gross proceeds of approximately $218.5 million. The offering included the full exercise of the underwriters' option to purchase an additional 1,500,000 shares, priced at $19.00 per share. The funds raised will support the company's development of targeted therapies for breast cancer, including their lead candidate, palazestrant, which is currently in Phase 3 clinical trials. This successful capital raise reflects strong investor confidence in Olema's pipeline and potential growth.
Read more →OLMAOlema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock
Olema Oncology has announced a public offering of 10 million shares of common stock priced at $19.00 each, expected to yield gross proceeds of about $190 million. The offering is set to close on November 20, 2025, pending customary conditions. Five financial firms are managing the offer, demonstrating robust market interest. This funding will bolster Olema's initiatives in developing therapies for breast cancer.
Read more →OLMA▲ +136.4%on this newsshared move
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Olema Oncology, a clinical-stage biopharmaceutical company, has announced plans for a public offering of common stock and pre-funded warrants. The offering is subject to market conditions and includes a provision for underwriters to purchase additional shares. No guarantees are provided for the timing or completion of this offering, which raises some uncertainty regarding its success. Olema continues to focus on developing targeted therapies for breast cancer and beyond.
Read more →OLMAOlema Oncology Reports Third Quarter 2025 Financial and Operating Results
Olema Oncology reported its financial and operational results for Q3 2025, highlighting the initiation of the Phase 3 OPERA-02 trial for palazestrant. The company also noted strong enrollment in the OPERA-01 trial and significant cash reserves. However, the net loss increased compared to the previous year, attributed to rising R&D expenses.
Read more →OLMAOlema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
Olema Oncology announced it will present a trial-in-progress poster for the Phase 3 OPERA-02 trial at the upcoming San Antonio Breast Cancer Symposium (SABCS 2025). The trial evaluates the efficacy of palazestrant combined with ribociclib for treating advanced ER+/HER2- breast cancer. The poster presentation is scheduled for December 12, 2025.
Read more →OLMA▼ -17%on this news
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
Olema Oncology has announced promising data from its Phase 1b/2 trial of palazestrant combined with ribociclib for treating ER+/HER2- metastatic breast cancer. The results indicate significant progression-free survival and tolerability, suggesting the regimen could become a new standard of care. The findings will be presented at the ESMO Congress 2025 in Berlin.
Read more →OLMA▲ +18.5%on this news· ran to +52% by day 3shared move
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
Olema Oncology has announced a clinical trial collaboration with Pfizer to evaluate the combination of palazestrant and atirmociclib in a Phase 1b/2 study for ER+/HER2- metastatic breast cancer. This partnership aims to assess the safety and effectiveness of the drug combination, with Olema leading the study. The agreement marks the second collaboration between the two companies, building on previous research efforts.
Read more →OLMAOlema Oncology Reports Second Quarter 2025 Financial and Operating Results • Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combin
Olema Oncology reported its second quarter 2025 financial results, highlighting the selection of a 90 mg daily dose of palazestrant for significant ongoing Phase 3 trials. Enrollment for the OPERA-01 trial is on track, with top-line data expected in late 2026, while the OPERA-02 trial is set to begin in Q3 2025. The company holds $361.9 million in cash, positioning it to support clinical advancements, although it experienced an increased net loss associated with R&D expenditures.
Read more →OLMAOlema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
Olema Oncology announced the selection of a 90 mg dose of palazestrant for the Phase 3 OPERA-01 monotherapy trial and the OPERA-02 combination trial with ribociclib for treating metastatic breast cancer. This decision comes after alignment with the FDA, reflecting confidence in the drug's efficacy. The OPERA-01 trial-in-progress poster will be showcased at the ASCO Annual Meeting, where details about the ongoing study will be shared. Top-line data from the OPERA-01 trial is anticipated in 2026, with a potential commercial launch planned for 2027.
Read more →OLMAOlema Oncology Reports First Quarter 2025 Financial and Operating Results • Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer on track for initiati
Olema Oncology has reported its financial and operational results for Q1 2025, highlighting progress in its pivotal Phase 3 trials for palazestrant. The company is set to initiate the OPERA-02 trial and continues with the OPERA-01 trial for metastatic breast cancer. It also presented promising preclinical data for its KAT6 inhibitor, OP-3136. With a strong financial position, Olema is well-positioned to advance its clinical pipeline, despite reporting a net loss for the quarter.
Read more →OLMAOlema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
Olema Oncology announced preclinical data showcasing the anti-tumor activity of OP-3136, a selective KAT6 inhibitor, in various solid tumor models including prostate, ovarian, and non-small cell lung cancer. The findings will be presented at the 2025 AACR Annual Meeting, reflecting the drug's potential in treating cancers beyond its initial focus on breast cancer. Patient recruitment is ongoing for a Phase 1 trial of OP-3136 as a monotherapy and in combination therapies. Results indicate sustained tumor regression in ovarian cancer and enhanced synergy when combined with other treatments.
Read more →OLMAOlema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
Olema Oncology announced that it will present preclinical data for OP-3136, a potent KAT6 inhibitor, at the AACR Annual Meeting in April 2025. The presentation will detail OP-3136's anti-tumor activity observed in prostate, ovarian, and non-small cell lung cancer models. The FDA cleared the IND application for OP-3136 in December 2024, and the company is currently enrolling patients in a Phase 1 clinical trial. This development highlights Olema's focus on targeted therapies for cancer patients.
Read more →OLMA▼ -7%on this news
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
Olema Oncology reported its fourth quarter and full year financial results for 2024, highlighting a strong cash position of $434.1 million and promising progress in its clinical trials, particularly with palazestrant for breast cancer. The company has initiated pivotal Phase 3 trials and is collaborating with Novartis. Despite the positive developments, Olema also reported increased net losses for the year due to rising clinical development expenses. The company aims to enhance patient enrollment and advance its drug candidates in 2025.
Read more →OLMAForward-looking statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that a
Olema is advancing its clinical pipeline with a focus on therapies for endocrine-driven cancers, including palazestrant and OP-3136. The company aims to establish palazestrant as a leading treatment for ER+/HER2- metastatic breast cancer, both as a monotherapy and in combination with other agents. With a solid financial position of approximately $434.1 million, Olema is actively accruing patients in ongoing clinical trials. However, multiple forward-looking statements highlight the inherent risks and uncertainties associated with their product development and timelines for approvals.
Read more →OLMAOlema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Olema Oncology, a clinical-stage biopharmaceutical company, has announced that its CEO Sean P. Bohen will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025. The presentation aims to showcase the company's commitment to improving breast cancer treatments through innovative therapies. Olema is currently advancing its lead candidate, palazestrant, in a Phase 3 clinical trial, signaling progress in its research and development efforts. The live webcast will be available for investors and interested parties to access the presentation.
Read more →OLMAOlema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary
Olema Pharmaceuticals has appointed Shawnte M. Mitchell, J.D., as its new Chief Legal Officer and Corporate Secretary. Ms. Mitchell brings two decades of experience in regulatory and business development within the biotechnology sector, previously holding senior positions at Genomatica, Zogenix, and Aptevo Therapeutics. Her expertise is expected to be instrumental as Olema advances its late-stage clinical programs, including its lead product candidate, palazestrant, aimed at treating breast cancer. The appointment is viewed positively as the company approaches significant development milestones.
Read more →OLMAOlema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. CEO Sean P. Bohen will discuss the company's advancements in targeted therapies for breast cancer, including their lead candidate palazestrant (OP-1250). A live webcast of the presentation will be available, and a recording will also be posted on the company's website. Olema is focused on enhancing patient outcomes through innovative therapies.
Read more →OLMAOlema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
Olema Oncology has presented updated clinical results for palazestrant in combination with ribociclib at the San Antonio Breast Cancer Symposium. The study shows promising efficacy, with a 6-month median progression-free survival rate of 73% in patients. Safety results align with existing ribociclib therapies, and there were no new safety signals reported. The results support the continued development of palazestrant in first-line treatment for ER+/HER2- advanced or metastatic breast cancer.
Read more →OLMA▼ -9.7%on this news· ran to -36% by day 3shared move
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor • Phase 1 clinical trial for OP-3136 to initiate in early 2025 SAN FRANCISCO, CA - (GLOBE NEWSWIR
Olema Oncology has announced that the FDA has cleared its Investigational New Drug application for OP-3136, a selective KAT6 inhibitor. The drug showed compelling activity in preclinical models and is expected to enter Phase 1 clinical trials in early 2025. Olema aims to improve outcomes in breast cancer and has a pipeline of therapies, including the lead product candidate palazestrant. The company is based in San Francisco and also operates in Cambridge, Massachusetts.
Read more →OLMAOlema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement • Clinical trial collaboration an
Olema Oncology has announced a new clinical trial collaboration and supply agreement with Novartis for a pivotal Phase 3 trial of palazestrant in combination with ribociclib, targeting frontline ER+/HER2- metastatic breast cancer. The initiation of this trial is expected in mid-2025. Additionally, Olema has secured a $250 million private placement to sustain its operations and fund further clinical studies. This agreement allows Olema to leverage Novartis's resources while retaining global commercial rights for palazestrant.
Read more →OLMAOlema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
Olema Pharmaceuticals announced that it will present new data on palazestrant combined with ribociclib at the upcoming San Antonio Breast Cancer Symposium. The presentation will focus on a Phase 1b/2 study involving patients with advanced ER+/HER2- breast cancer. Additionally, Olema will hold a conference call on December 10 to discuss these findings with the investment community. Palazestrant has shown promising results in clinical research, including its potential in effectiveness and safety as a treatment option.
Read more →OLMA▼ -9.3%on this news· ran to -28% by day 3
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update • Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enh
Olema Oncology reported its financial results for Q3 2024, highlighting significant developments in their drug pipeline, including promising preclinical data for OP-3136 and upcoming presentations at major cancer symposia. The company expects to submit an Investigational New Drug application for OP-3136 by the end of the year, with clinical trials anticipated to start in early 2025. Despite a net loss of $34.6 million primarily due to increased clinical development costs, Olema remains financially robust with $214.8 million in marketable securities.
Read more →OLMAOlema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
Olema Pharmaceuticals presented promising preclinical data for OP-3136, a KAT6 inhibitor, which demonstrated significant anti-tumor activity in combination with palazestrant. The findings, to be showcased at ENA 2024, indicate that OP-3136 not only inhibits cell growth effectively but also synergizes with other therapies, potentially enhancing treatment options for patients with ER+/HER2- breast cancer. An IND submission for OP-3136 is anticipated by the end of 2024, reinforcing the company's commitment to advancing its clinical pipeline.
Read more →OLMAOlema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Olema Oncology has announced the presentation of multiple preclinical combination data at the upcoming 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The presentations will focus on various combination therapies in ER+/HER2- breast cancer models, including palazestrant, a dual-action breast cancer treatment. The company aims to highlight its recent advancements in targeted therapies at this prominent international conference. Detailed information about the presented posters will also be made available on their website.
Read more →OLMAAdvancing medicines for breast cancer and beyond Corporate Overview September 2024 Forward-looking statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Priva
The presentation outlines the company's advancements in developing therapies for breast cancer, specifically highlighting the potential of palazestrant (OP-1250) as a backbone treatment for ER+/HER2- breast cancer. It also introduces a new KAT6 inhibitor, expected to have a substantial impact on treatment options. However, the company acknowledges the inherent risks and uncertainties associated with the drug development process and existing limitations in current therapies. The management's expertise is emphasized as a key asset in navigating these challenges.
Read more →OLMAOlema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
Olema Pharmaceuticals, Inc. will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024. The event will feature a fireside chat format and is aimed at providing insights into Olema's commitment to women's cancer therapies. The company is currently advancing its lead product candidate, palazestrant, in a Phase 3 clinical trial, along with another candidate, OP-3136. A live webcast of the event will be available on their investor relations website.
Read more →OLMAOlema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update • Presented promising interim clinical results from the ongoing study of palazestrant in combination with ribociclib at th
Olema Oncology reported its second quarter 2024 financial results, highlighting promising interim results from a clinical trial studying palazestrant in combination with ribociclib. The company announced a preliminary clinical benefit rate of 85% among participants and confirmed the successful completion of IND-enabling studies for its KAT6 inhibitor (OP-3136), with an IND application expected by late 2024. Despite maintaining a strong cash position of $239.1 million, Olema's net loss has increased due to greater expenditures on clinical development. The company plans to present more detailed results at future medical meetings.
Read more →OLMAOlema Oncology to Participate in Upcoming Investor Conferences in June
Olema Pharmaceuticals, Inc. (OLMA) announced its participation in two upcoming investor conferences scheduled for June 2024. The conferences include the Jefferies Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference, where Olema's management will engage in fireside chats. The presentations will also be available via live webcasts on their investor relations website. This engagement highlights Olema's commitment to improving outcomes for women with cancer through their developing therapies.
Read more →OLMAOlema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress • Across 50 treated patients, palazestrant (OP-1250) in combination wit
Olema Oncology has announced promising interim results from a Phase 1b/2 study of palazestrant in combination with ribociclib for treating ER+/HER2- metastatic breast cancer. The study, presented at the 2024 ESMO Breast Cancer Congress, showed an 85% clinical benefit rate across treated patients, with no new safety concerns. The combination treatment highlighted favorable pharmacokinetics and sustained anti-tumor activity. The company aims to further develop palazestrant as a potential standard therapy for advanced breast cancer.
Read more →OLMAOlema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update • Completed enrollment in 60-patient Phase 1b/2 clinical studies of palazestrant in combination with each of ribociclib and
Olema Oncology has reported its first quarter 2024 financial results, revealing a completed enrollment in a 60-patient Phase 1b/2 clinical trial of palazestrant in combination with ribociclib and palbociclib. The company anticipates presenting new clinical data at the upcoming ESMO Breast Cancer Annual Congress in May 2024. Olema has a strong cash position of $249 million, although it also reported an increased net loss attributed to higher research and development expenses. The company is advancing its KAT6 inhibitor program, OP-3136, with plans to file an IND application with the FDA in late 2024.
Read more →OLMAOlema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
Olema Oncology has announced that it will present new clinical data regarding palazestrant in combination with ribociclib at the 2024 ESMO Breast Cancer Annual Congress. This data comes from an ongoing Phase 1b/2 clinical study targeting patients with ER+, HER2- advanced breast cancer. Palazestrant has already shown promise in clinical trials and received FDA Fast Track designation for its potential. The presentation will take place on May 16, 2024, and a copy of the poster will be available on Olema's website.
Read more →OLMAOlema Oncology to Participate in Upcoming Investor Conferences in May
Olema Oncology, a clinical-stage biopharmaceutical company, announced its participation in several upcoming investor conferences in May 2024, including the BofA Securities Health Care Conference and the H.C. Wainwright 2nd Annual BioConnect Investor Conference. These events will provide an opportunity for Olema's management to communicate the company's progress in developing targeted therapies for women's cancers. They will be holding various formats such as presentations and fireside chats, which aim to enhance investor engagement by sharing insights into their targeted therapies.
Read more →OLMA▲ +5.3%on this news
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
Olema Pharmaceuticals, Inc. announced that their CEO, Sean P. Bohen, will participate in a panel discussion on breast cancer at the 2024 Canaccord Genuity Horizons in Oncology Virtual Conference. The event is scheduled for April 15, 2024, at 2:00 p.m. ET. Olema, a clinical-stage biopharmaceutical company, aims to transform cancer treatment for women by developing targeted therapies. Their pipeline includes innovative treatments such as palazestrant and a potent KAT6 inhibitor.
Read more →OLMAOlema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update • Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/
Olema Oncology reported its financial results for Q4 and full year 2023, highlighting promising clinical results for its drug palazestrant in treating ER+/HER2- breast cancer. The company initiated a pivotal Phase 3 trial and has fully enrolled a Phase 2 study for palazestrant in combination with CDK4/6 inhibitors, with results expected at the ESMO Congress in May 2024. Despite increased losses attributed to clinical operations, Olema maintains a strong financial position with substantial cash reserves.
Read more →OLMAOlema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
Olema Oncology has announced the publication of significant data regarding its drug palazestrant (OP-1250) in the journal Molecular Cancer Therapeutics. This research highlights palazestrant's efficacy in inhibiting both wild-type and mutant ER+ breast cancer, demonstrating promising results in pre-clinical studies. The drug is currently undergoing clinical trials for treatment-resistant breast cancer, with a focus on enhancing outcomes for women. Notably, palazestrant has received FDA Fast Track designation, emphasizing its potential importance in addressing unmet medical needs in oncology.
Read more →OLMAOlema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in
Olema Oncology has nominated OP-3136, an orally bioavailable KAT6 inhibitor, as a development candidate targeted at breast cancer and other cancers. The candidate showed strong anti-tumor activity alone and in synergy with palazestrant and CDK4/6 inhibitors in preclinical studies. Olema aims to initiate IND-enabling studies with the goal of advancing OP-3136 into clinical development by the end of 2024. This nomination signifies a commitment to enhancing treatment options for women with cancer.
Read more →OLMAOlema Oncology JP Morgan Conference January 2024 Forward-Looking Statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Ac
Olema Oncology presented forward-looking statements at the JP Morgan Conference in January 2024, outlining its clinical development plans for palazestrant, an investigational treatment for ER+/HER2- metastatic breast cancer. The company aims to execute pivotal trials and expand research on its KAT6 inhibitor. Despite promising data, the statements also highlight uncertainties and risks inherent in drug development, including financial and regulatory challenges.
Read more →OLMAOlema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
Olema Pharmaceuticals, Inc. announced that Sean P. Bohen, M.D., President and CEO, will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The presentation will be focused on Olema's drug development strategies, particularly for women's cancers. Olema's lead candidate, palazestrant, is undergoing evaluation in multiple clinical trials and has been granted FDA Fast Track designation for certain breast cancer treatments.
Read more →OLMA▼ -9.2%on this news
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies • Palazestrant (OP-1250) in combination with the CDK 4/6 inhibito
Olema Oncology announced promising interim results from Phase 1b/2 studies of palazestrant (OP-1250) in combination with CDK4/6 inhibitors ribociclib and palbociclib. The studies demonstrated favorable tolerability profiles and no significant drug-drug interactions, indicating palazestrant's potential as a key endocrine therapy for ER+/HER2- breast cancer. Olema is moving towards pivotal trials, aiming to transform the treatment standard for women’s cancers.
Read more →OLMA▼ -9.2%on this news
Olema SABCS December 2023 Presentation
Olema's presentation at SABCS December 2023 highlighted their research on palazestrant (OP-1250), a potential best-in-class endocrine therapy for ER+/HER2- metastatic breast cancer. The company provided positive data indicating palazestrant's anti-tumor activities in combination with CDK4/6 inhibitors, showing no significant drug-drug interactions or dose-limiting toxicities. Ongoing Phase 2 combination studies support the further development of palazestrant, with plans to initiate pivotal trials by the end of 2024.
Read more →OLMAOlema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
Olema Pharmaceuticals, Inc. (OLMA) announced the presentation of new clinical data for palazestrant at the upcoming 2023 San Antonio Breast Cancer Symposium. The data includes a Phase 1b study in combination with ribociclib, a Phase 2 study with palbociclib, and an ongoing Phase 3 trial (OPERA-01) assessing palazestrant. These presentations will take place on December 7, 2023, and will provide key insights into palazestrant's potential in treating advanced breast cancer. An investor conference call is scheduled for December 8, 2023, to discuss these findings further.
Read more →OLMA▲ +10.4%on this news
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update OPERA-01 pivotal Phase 3 monotherapy clinical trial on track, with clinical site activation ongoing and first patient expected to
Olema Oncology reported its financial results for the third quarter of 2023, highlighting a cash position of $276.9 million and a reduced net loss of $21.5 million compared to the same quarter last year. The company is advancing its OPERA-01 Phase 3 clinical trial, with clinical site activations ongoing. Olema's Phase 2 trial of palazestrant is rapidly enrolling participants, and new data is expected to be presented at the upcoming SABCS symposium in December. The report underscores a continued focus on developing targeted therapies for women's cancers.
Read more →OLMA▲ +12.4%on this newsshared move
Olema Oncology to Participate in Upcoming Investor Conferences in November
Olema Oncology, a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences in November. The CEO, Dr. Sean P. Bohen, will engage in a Fireside Chat at the Jefferies London Healthcare Conference and the Evercore ISI HealthCONx Conference. The events aim to boost investor engagement and visibility for the company as it focuses on targeted therapies for women's cancers. Live webcasts of the sessions will be available on Olema's investor relations website, ensuring wider access to stakeholders.
Read more →OLMAOlema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at
Olema Oncology announced positive results from a Phase 2 study of palazestrant, an oral complete estrogen receptor antagonist and selective ER degrader, for ER+/HER2- metastatic breast cancer. The drug achieved a median progression-free survival of 4.6 months with a clinical benefit rate of 40% among 86 heavily pretreated patients. No significant toxicities were reported, but some patients did experience Grade 4 neutropenia. Olema plans to initiate a pivotal Phase 3 trial for palazestrant, suggesting confidence in its potential as a leading therapy in this space.
Read more →OLMAOlema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors Mr. Garland brings significant industry expertise with a long track record of successful launches
Olema Oncology has appointed Scott Garland to its Board of Directors, who brings over 30 years of biopharmaceutical experience, particularly in oncology. Garland's leadership roles include significant contributions to the successful launch of therapies like Andexxa and cabozantinib. His appointment coincides with Olema advancing its lead candidate, palazestrant, into Phase 3 trials, highlighting the company's commitment to improving treatments for women's cancers. The leadership is optimistic about Garland's potential impact on their strategic initiatives.
Read more →OLMA▼ -16.5%on this newsshared move
Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
Olema Pharmaceuticals has announced that it will present Phase 2 monotherapy study results of its drug, palazestrant (OP-1250), at the 2023 ESMO Congress. The presentation will cover the drug's efficacy as a complete estrogen receptor antagonist and selective ER degrader for treating metastatic breast cancer. The oral session is scheduled for October 22, 2023, and will feature Dr. Nancy U. Lin as the lead presenter. Following the congress, Olema will hold an investor conference call to discuss the findings and ongoing studies.
Read more →OLMAOlema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
Olema Oncology has announced promising preclinical findings on its novel KAT6 inhibitor compounds, highlighting their potent anti-tumor activity against KAT6-amplified breast cancer. These compounds showed over 250-fold selectivity for KAT6A and KAT6B while effectively inhibiting cell proliferation in relevant models. The KAT6 compounds exhibit desirable pharmacokinetics and synergistic effects when combined with existing therapies like palbociclib. The findings were presented at the 2023 AACR-NCI-EORTC International Conference in Boston.
Read more →OLMAOlema Oncology Announces Expansion of Collaboration Agreement with Novartis Amended clinical collaboration and supply agreement increases the palazestrant/ribociclib combination Phase 1/2 clinical study size to approxima
Olema Oncology has announced an expansion of its clinical collaboration agreement with Novartis to increase the size of its Phase 1/2 study of palazestrant in combination with ribociclib. The study will now involve approximately 60 patients, aiming to support regulatory approval for first-line treatment of advanced or metastatic breast cancer. Olema's recent progress includes completing Phase 1b dose escalation and moving into Phase 2 dose expansion. This collaboration marks a significant step in the development of novel therapies for women's cancers.
Read more →OLMAOlema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Olema Pharmaceuticals announced a poster presentation of new KAT6 inhibitors at the upcoming AACR-NCI-EORTC conference, showcasing their anti-tumor activity in ER+ breast cancer models. The presentation is scheduled for October 12, 2023, and aligns with Olema's mission to develop targeted therapies for women's cancers. The KAT6 program has been developed in collaboration with Aurigene Oncology, following a licensing agreement that aims to advance the discovery and commercialization of these inhibitors. Olema emphasizes the innovative potential of these compounds amidst several operational risks.
Read more →OLMA▲ +19.5%on this newsshared move
Olema Oncology Announces Combined Financing for Up to $180 Million $130 million equity private placement led by Paradigm BioCapital with participation by Lightspeed Venture Partners, Deep Track Capital, BVF Partners L.P.
Olema Oncology announced a substantial financing deal comprising a $130 million equity private placement and a senior secured credit facility of up to $50 million. The deal, led by Paradigm BioCapital with participation from several high-profile investors, is expected to enhance Olema's financial position significantly. Proceeds from the financing will primarily support the development of palazestrant (OP-1250) and facilitate ongoing clinical trials. This funding positions Olema to continue operations smoothly into 2027.
Read more →OLMAOlema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update Initiation of OPERA-01 pivotal Phase 3 monotherapy clinical trial on track; expecting to enroll first patient in fourth quarter N
Olema Oncology reported financial results for Q2 2023, highlighting key corporate developments including the initiation of the OPERA-01 pivotal Phase 3 trial, which is set to test palazestrant as a monotherapy. Enrollment for the trial is expected to begin in the fourth quarter of this year. The company reported a net loss of $20.1 million, a decrease from the previous year's loss, and has sufficient cash reserves to fund operations until mid-2025. Upcoming milestones include presenting mature Phase 2 monotherapy data at the ESMO Congress in October.
Read more →OLMAOlema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference
Olema Oncology announced that its CEO, Sean P. Bohen, will participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023. The company focuses on developing targeted therapies for women's cancers, with its lead candidate, OP-1250, currently in clinical trials. OP-1250 has received FDA Fast Track designation aimed at treating specific types of breast cancer, marking a significant step in its development. A live webcast of the event will be available for interested stakeholders.
Read more →OLMAOlema Oncology to Present at the 2023 Jefferies Healthcare Conference
Olema Pharmaceuticals, Inc. has announced that its CEO, Sean P. Bohen, will participate in a Fireside Chat at the upcoming 2023 Jefferies Healthcare Conference in New York on June 7, 2023. The chat will be accessible via a live webcast and archived for at least 30 days for future reference. Olema is focused on the development of targeted therapies for women's cancers, notably its lead candidate OP-1250, which is currently in clinical trials. OP-1250 aims to treat ER+/HER2- metastatic breast cancer and has received FDA Fast Track designation.
Read more →OLMAOlema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update Initiation of first pivotal Phase 3 monotherapy clinical trial of OP-1250 in second- and third-line metastatic breast cancer plann
Olema Oncology reported its financial results for the first quarter of 2023 and announced significant progress in its clinical development pipeline. The company is on track to initiate its first pivotal Phase 3 trial of OP-1250, targeting ER+/HER2- metastatic breast cancer, in the latter half of the year. Olema's cash reserves of $186 million are expected to fund operations until 2025. However, the company experienced an increase in net losses, primarily due to rising R&D costs and restructuring expenditures.
Read more →OLMAOlema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER
Olema Oncology has announced interim results from a Phase 1b/2 study of OP-1250 combined with the CDK4/6 inhibitor palbociclib for ER+/HER2- metastatic breast cancer. The results showed that OP-1250 was well tolerated and displayed no adverse drug interactions with palbociclib, contributing to its profile as a potential best-in-class therapy. Out of the 29 patients treated so far, significant anti-tumor activities and a clinical benefit rate of 42% were noted. The trial is ongoing with further patient enrollment expected.
Read more →OLMA▲ +10.7%on this newsshared move
Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update
Olema Oncology reported its first quarter financial results and an update on its clinical trials. The company is set to initiate a pivotal Phase 3 clinical trial for its lead candidate OP-1250 in treating ER+/HER2- metastatic breast cancer in the second half of 2023. They also plan to present interim Phase 2 results at the 2023 ESMO Breast Cancer Annual Congress. Despite a net loss increase for the quarter, Olema's cash reserves are sufficient to sustain operations until 2025.
Read more →OLMAOlema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress
Olema Pharmaceuticals, Inc. announced that it will present a poster featuring its drug OP-1250 at the ESMO Breast Cancer Annual Congress scheduled from May 11-13, 2023, in Berlin. The presentation will detail a phase 1b/2 study of OP-1250, which acts as a complete estrogen receptor antagonist and selective ER degrader for treating metastatic breast cancer. OP-1250 has garnered FDA Fast Track designation, showcasing its importance in addressing ER+/HER2- metastatic breast cancer.
Read more →OLMA▲ +7.7%on this news
Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference
Olema Oncology announced that its CEO, Sean Bohen, will participate in a panel discussion on ER+/HER2- breast cancer at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference. This event is scheduled for April 20, 2023, at 2:00 p.m. ET. Olema is focused on developing targeted therapies for women's cancers, with its lead candidate OP-1250 currently undergoing clinical trials. OP-1250 has received FDA Fast Track designation for its potential in treating metastatic breast cancer.
Read more →OLMAOlema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update Significant progress made advancing lead program, OP-1250, with more than 170 patients treated to date Initiating f
Olema Oncology has reported its financial results for the fourth quarter and full year ended December 31, 2022, stating significant progress with its lead program OP-1250. The company is focusing on late-stage clinical development, which includes initiating its first pivotal Phase 3 trial later this year. However, a restructuring will lead to a 25% workforce reduction as part of its strategic shift. Olema maintains a strong cash position expected to support its operations through 2025, despite reporting increased net losses for the year.
Read more →OLMAOlema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference
Olema Oncology, a clinical-stage biopharmaceutical firm, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023. Sean Bohen, M.D., Ph.D., will lead the presentation, which will be available via live webcast on Olema's investor relations website. The company focuses on developing targeted therapies for women's cancers, with its lead candidate, OP-1250, currently in clinical trials and holding FDA Fast Track designation for treating ER+/HER2- metastatic breast cancer.
Read more →OLMA▼ -8.6%on this news
Olema Oncology to Participate at Upcoming Investor Conferences
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) has announced its participation in upcoming investor conferences, highlighting its commitment to engaging with the investment community. CEO Sean Bohen will partake in a fireside chat at the Citi 2023 Virtual Oncology Leadership Summit, while CFO Shane Kovacs will join a corporate panel at Cowen's Annual Healthcare Conference. Furthermore, Olema's lead product candidate, OP-1250, is currently under evaluation in clinical trials and has received FDA Fast Track designation.
Read more →OLMA▲ +7.8%on this newsshared move
Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference
Olema Oncology, a clinical-stage biopharmaceutical company, announced that its CEO, Sean Bohen, will present at the 41st Annual J.P. Morgan Healthcare Conference in January 2023. The presentation will take place in San Francisco and will be accessible via a live webcast. Olema is focused on developing targeted therapies for women’s cancers, with its lead product candidate, OP-1250, currently undergoing clinical trials and having received FDA Fast Track designation. This conference is a key event for biotech companies to showcase their advancements.
Read more →OLMA▲ +5.2%on this news
Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study
OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- breast cancer, with no dose-limiting toxicities, and no observed drug-drug interaction No induced metabolism of palbociclib and no safety interaction was observed Overall tolerability profile
Read more →OLMAOlema Oncology Announces Poster Presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS)
SAN FRANCISCO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced two poster presentations on OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in devel
Read more →OLMAOlema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update Presented preliminary results from OP-1250 Phase 1/2 dose expansion study demonstrating favorable tolerability, high drug exposure
Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update SAN FRANCISCO, November 8, 2022 - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology," Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development a
Read more →OLMAOlema Oncology to Present at Upcoming Investor Conferences in November
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cance
Read more →OLMA▲ +5%on this news
Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial
OP-1250 continues to demonstrate favorable tolerability, high drug exposure, and strong anti-tumor activity in preliminary Phase 1/2 study results presented at the 34th EORTC-NCI-AACR Symposium Initial clinical data for OP-1250 in combination with CDK 4/6 inhibitor palbociclib e
Read more →OLMA▼ -5.3%on this news
Olema Oncology Announces Upcoming Clinical Data Poster Presentation at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
SAN FRANCISCO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the Company will present updated clinical results from the OP-1250-001 study at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and
Read more →OLMAOlema Oncology to Present at H.C. Wainwright 24th Annual Global Investment Conference
SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s canc
Read more →OLMAOlema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer
SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), into Phase 2 clinical dev
Read more →OLMAOlema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update Received Fast Track designation from U.S. FDA for OP-1250 for the treatment of ER+/HER2- metastatic breast cancer Reported progre
Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update SAN FRANCISCO, August 9, 2022 - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology," Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development an
Read more →OLMAOlema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference
SAN FRANCISCO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announ
Read more →OLMA▲ +20.6%on this news
Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer
SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OP-1250, the Company's novel, oral complete estrogen rec
Read more →OLMA▲ +8.5%on this news
Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program
Favorable tolerability with no grade 3/4 neutropenia and encouraging anti-tumor activity across Phase 1b monotherapy expansion Combinability with CDK4/6i palbociclib demonstrated across initial dose escalation cohorts, including no dose limiting toxicities and no induced metabol
Read more →OLMA▲ +8.5%on this news
Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies
SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an exclusive global license agreement to research, develop and commercialize novel sma
Read more →OLMA▲ +10.1%on this news· ran to +24% by day 3
Olema Oncology to Present at Jefferies Healthcare Conference
SAN FRANCISCO, May 24, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announc
Read more →OLMA▼ -7.6%on this news
Olema Oncology Reports First Quarter 2022 Financial Results and Provides Corporate Update Phase 1/2 trial of OP-1250 continues to enroll patients in the dose expansion stage, with selection of Recommended Phase 2 Dose ex
Olema Oncology Reports First Quarter 2022 Financial Results and Provides Corporate Update SAN FRANCISCO, May 9, 2022 - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology," Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and co
Read more →OLMAOlema Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 18, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s canc
Read more →OLMA▲ +5.4%on this news
Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the Canaccord Genuity
Read more →OLMAOlema Oncology Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022
SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today annou
Read more →OLMAOlema Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Presented Phase 1a proof-of-concept data for OP-1250 in metastatic, ER+ / HER2- breast cancer, with demonstrated at
Olema Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update SAN FRANCISCO, February 28, 2022 - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology," Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discover
Read more →OLMAOlema Oncology to Present at Cowen 42nd Annual Health Care Conference
SAN FRANCISCO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at the Cowen 42nd Annual
Read more →OLMA▲ +9.4%on this news· ran to +19% by day 1shared move
Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical Officer
• Dr. Zojwalla brings extensive and diverse experience in clinical development and regulatory strategy for novel oncology therapies • As part of planned leadership transition, former CMO Pamela Klein, M.D., will become a senior advisor and member of Olema’s Scientific Advisory B
Read more →OLMA▼ -5.8%on this news· ran to -23% by day 3
Olema Oncology to Present at 40th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at the 40th Annual J.P. M
Read more →OLMA▼ -60%on this news
Olema Oncology Announces First Clinical Data on OP-1250 in Advanced ER+ / HER2- Breast Cancer
Successful completion of dose-escalation stage of ongoing Phase 1/2 clinical study; OP-1250 demonstrated highly attractive pharmacokinetics, favorable tolerability, and clear efficacy signals Robust anti-tumor activity, including three partial responses (two confirmed and one un
Read more →OLMAOlema Oncology Issues Statement Regarding Falsified Information Circulating on Social Media
SAN FRANCISCO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, has been ale
Read more →OLMA▼ -6.6%on this news
Olema Oncology to Present New Data on OP-1250 at 2021 San Antonio Breast Cancer Symposium
Interim pharmacokinetic, safety and tolerability, and preliminary efficacy data from Phase 1 dose escalation to be presented Company to host investor webcast at 8:30 a.m. ET on Wednesday, December 8, 2021 SAN FRANCISCO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, I
Read more →OLMAOlema Oncology Reports Third Quarter 2021 Financial Results and Provides Corporate Update Completed dose-escalation stage of Phase 1/2 clinical trial of OP-1250 in patients with metastatic, ER+ / HER2- breast cancer Inte
Olema Oncology Reports Third Quarter 2021 Financial Results and Provides Corporate Update SAN FRANCISCO, November 10, 2021 - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology," Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development
Read more →OLMAOlema Oncology to Present at Two Upcoming Investor Conferences
SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announ
Read more →OLMAOlema Oncology Announces Trials in Progress Poster on OP-1250 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today annou
Read more →OLMAOlema Oncology to Present Data on OP-1250 at the 2021 JCA-AACR Precision Cancer Medicine International Conference
SAN FRANCISCO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today annou
Read more →OLMAOlema Oncology to Present at Morgan Stanley 19th Annual Global Healthcare Conference
SAN FRANCISCO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announ
Read more →OLMAOlema Oncology Reports Second Quarter 2021 Financial Results and Provides Corporate Update Presentation of preliminary Phase 1/2 dose-escalation data for OP-1250 in patients with metastatic, ER+ / HER2- breast cancer pla
Olema Oncology Reports Second Quarter 2021 Financial Results and Provides Corporate Update SAN FRANCISCO, August 10, 2021 - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology," Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development a
Read more →OLMAOlema Oncology to Present at Canaccord Genuity 41st Annual Growth Conference
SAN FRANCISCO, July 28, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announ
Read more →OLMAOlema Oncology to Participate at the Jefferies 2021 Virtual Healthcare Conference
SAN FRANCISCO, May 18, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announc
Read more →OLMAOlema Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Update OP-1250 continues to advance in dose-escalation stage of Phase 1/2 clinical trial in patients with metastatic, ER+ / HER2- breast
Olema Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Update SAN FRANCISCO, May 11, 2021 - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology," Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and c
Read more →OLMAOlema Oncology Appoints Oncology Biotech Executive Yi Larson, MBA, to Board of Directors
Ms. Larson Brings Significant Biotech Operational Leadership and Global Healthcare Banking Expertise to Olema as the Company Continues to Advance Its Pipeline Longstanding Olema Director Dr. Frank McCormick to Transition from Board of Directors and Return to His Position as Chai
Read more →OLMAOlema Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates Advancing OP-1250 in metastatic, ER+ / HER2- breast cancer Phase 1/2 clinical trial Clinical trial agreements anno
Olema Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates SAN FRANCISCO, March 17, 2021 - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology," NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,
Read more →OLMAOlema Oncology Announces Late-Breaking Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021
SAN FRANCISCO, March 10, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster
Read more →OLMAOlema Oncology to Participate at Upcoming Virtual Investor Conferences
SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announ
Read more →OLMAOlema Oncology to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference
SAN FRANCISCO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announ
Read more →OLMAOlema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020
SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced two poster
Read more →OLMAOlema Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the closin
Read more →OLMAOlema Oncology Announces Pricing of Initial Public Offering
SAN FRANCISCO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the pricin
Read more →Competitive Position
How OLMA ranks across every disease it competes inCompetitive Position is a premium feature
See how OLMA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial